Top Markets
Coin of the day
Australian Clinical Labs Limited Australian Clinical Labs Limited

Australian Clinical Labs Limited

ACL
Kedudukan dalam Saham #15163
Australian Clinical Labs Limited operates across Australia, delivering a... Australian Clinical Labs Limited operates across Australia, delivering a diverse range of diagnostic pathology services. The company's extensive portfolio encompasses standard examinations alongside advanced molecular genetics, including Harmony NIPT and initial trimester screenings, as well as genetic carrier screening. Furthermore, it provides detailed analyses in chemical, tissue (histopathology), and cellular (cytopathology) pathology; specialized tests for hematology, allergies, and immunology; and comprehensive serology and microbiology services. ACL also performs infectious molecular testing, cardiac diagnostic assessments, functional pathology, veterinary pathology, and commercial drug and alcohol screening. These essential services are supplied to both private and public hospitals throughout the nation. The company was founded in 2020 and maintains its primary operational base in Clayton, Australia.
Harga Saham
$1.98
Modal Pasaran
$368.99M
Perubahan (1 hari)
0.90%
Perubahan (1 tahun)
11.38%
Negara
AU
Perdagangan Australian Clinical Labs Limited (ACL)

Kategori

Hasil untuk Australian Clinical Labs Limited (ACL)
Hasil pada Sep 2026 TTM: 0
Menurut laporan kewangan terkini daripada Australian Clinical Labs Limited, hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Australian Clinical Labs Limited dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
$46.34B -
US
$25.11B -
US
- -
CN
$2.71B -
US
$4.55B -
US